On May 15, Mallinckrodt officially opened a new Global Medical Device Engineering Facility at its campus at the College Business and Technology Park in Blanchardstown, Dublin 15, Ireland. The company is consolidating global device research and development (R&D) activities to this new facility, creating 45 highly skilled jobs in a range of disciplines including product design, core electronics, electro-mechanical engineering and software development.
The opening of this new R&D facility brings Mallinckrodt’s total investment at the Blanchardstown location to €95 million, and with these 45 positions the company is creating 120 new jobs in a variety of areas including manufacturing, supply chain management and other support functions. Leo Varadkar, TD, Minister for Social Protection, and Mallinckrodt President and CEO Mark Trudeau joined other dignitaries to commemorate the official opening.
Commenting, Minister Varadkar said, “I am very pleased to mark the opening of Mallinckrodt’s Global Device Engineering facility at its new location in Blanchardstown. It’s great to see a medical device R&D facility like this investing in west Dublin. Mallinckrodt is creating jobs and enhancing Ireland’s reputation as an important hub for R&D, which is a key plank in the Government’s economic development strategy. Ultimately, the devices developed here in this facility will make a real difference to the lives of patients both in Ireland and internationally.”
“Mallinckrodt has had a significant manufacturing and business presence in Ireland for almost a quarter of a century,” said Trudeau. In that time, our employees here have been, and continue to be, a tremendous asset to our global operations. This new facility allows us to centralize our device R&D skills and expertise in developing the next generation of products for a number of important and rare conditions to make a significant difference to the lives of patients.”
During the opening celebration Mallinckrodt also announced a new corporate partnership with the Coolmine Therapeutic Community, which provides day and residential services to men and women with problematic substance use and their families in Ireland. Mallinckrodt committed initial financial support of €15,000 to Coolmine.
Commenting, Dr. David Keenan, Vice President, Global External Supply and Managing Director, Mallinckrodt Pharmaceuticals, Ireland, said, “The Coolmine Therapeutic Community provides critical supports and services for families and individuals encountering very serious challenges in their lives. We are pleased to support them in their essential work.”
Pictured above: Leo Varadkar, TD, Minister for Social Protection; Mark Trudeau, President and Chief Executive Officer, Mallinckrodt; Dr. David Keenan, Vice President, Global External Supply and Managing Director, Mallinckrodt Pharmaceuticals, Ireland